Johnson & Johnson /zigman2/quotes/201724570/composite JNJ +0.10% expects to share details from the Phase 3 clinical trial for its COVID-19 vaccine candidate "early next week," according to remarks made by CEO Alex Gorsky on Tuesday during an earnings call. J&J's stock was up 3.0% in trading on Tuesday afternoon. The company's experimental COVID-19 adenovirus-based vaccine is currently being tested in late-stage clinical trials, and results are being closely watched for several reasons, including that it's a single-dose vaccine and there are ongoing supply issues for doses of the BioNTech SE /zigman2/quotes/214419716/composite BNTX -1.61% /Pfizer Inc. /zigman2/quotes/202877789/composite PFE +0.21% and Moderna Inc. /zigman2/quotes/205619834/composite MRNA +2.48% vaccines in the U.S. (Both of the currently authorized coronavirus vaccines in the U.S. require two doses.) "We're certainly hopeful that you're going to see a durable and a sustainable and patent response, particularly from our [adenovirus-based] vector approach," Gorsky told investors, according to a FactSet transcript of the call. J&J's stock is up 15.3% over the past 12 months, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -2.45% has gained 17.0%.